ARTICLE | Clinical News
OHR/AVR118: Phase II data
April 1, 2013 7:00 AM UTC
An open-label, Canadian Phase II trial in 18 patients with stage III/IV solid tumors with cachexia showed that once-daily subcutaneous injections of 4 mL OHR/AVR118 missed the primary endpoint of impr...